MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update
$30.5 million in gross proceeds raised; operating cash runway through 2025
NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues
Related news for (MDWD)
- MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
- MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
- MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
- MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care